Draft Guidance on Glyburide

Contains Nonbinding Recommendations

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Glyburide

Form/Route: Tablet; Oral

Recommended studies: 2 Studies

1. Type of study: Fasting
   Design: Single-dose, two-way crossover *in-vivo*
   Strength: 6 mg
   Subjects: Healthy males and nonpregnant females, general population
   Additional Comments: To avoid hypoglycemic episodes in healthy volunteers, the drug products should be administered with 240 mL of a 20% glucose solution in water, followed by 60 mL of the glucose solution administered every 15 minutes for up to 4 hours after dosing.

2. Type of study: Fed
   Design: Single-dose, two-way crossover *in-vivo*
   Strength: 6 mg
   Subjects: Healthy males and nonpregnant females, general population
   Additional Comments: Please see comment above. Please also refer to the Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analytes to measure (in appropriate biological fluid): Glyburide in plasma

Bioequivalence based on (90% CI): Glyburide

Waiver request of in-vivo testing: 1.5 mg and 3 mg based on (i) acceptable bioequivalence studies on the 6 mg strength, (ii) acceptable in-vitro dissolution testing of all strengths, and (iii) proportional similarity of the formulations across all strengths.

Please refer to the Mirtazapine Tablet Draft Guidance for additional information regarding waivers of in-vivo testing.

Dissolution test method and sampling times:
Please note that a Dissolution Methods Database is available to the public at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each for all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Mar 2012